 | Up a level |
Matsusaka, S; Wu, A H; Cao, S; Hanna, D L; Chin, K; Yang, D; Zhang-Wu, Xiaxia; Ning, Y; Stintzing, S; Sebio, A; Sunakawa, Y; Stremitzer, S; Yamauchi, S; Okazaki, S; Berger, Martin Dave; Parekh, A; Miyamoto, Y; Mizunuma, N; Lenz, H-J (2018). Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics journal, 18(2), pp. 262-269. Nature Publishing Group 10.1038/tpj.2017.9
Matsusaka, S; Cao, S; Hanna, D L; Sunakawa, Y; Ueno, M; Mizunuma, N; Zhang-Wu, Xiaxia; Yang, D; Ning, Y; Stintzing, S; Sebio, A; Stremitzer, S; Yamauchi, S; Parekh, A; Okazaki, S; Berger, Martin Dave; El-Khoueiry, R; Mendez, A; Ichikawa, W; Loupakis, F; ... (2017). CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics journal, 17(6), pp. 543-550. Nature Publishing Group 10.1038/tpj.2016.59
Sunakawa, Y; Cao, S; Volz, N B; Berger, Martin Dave; Yang, D; Parekh, A; Zhang-Wu, Xiaxia; Matsusaka, S; Ning, Y; Stremitzer, S; Stintzing, S; Sebio, A; Okazaki, S; Wakatsuki, T; Azuma, M; Watanabe, M; Koizumi, W; Wu, A H; Lenz, H-J (2017). Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. Pharmacogenomics journal, 17(6), pp. 528-534. Nature Publishing Group 10.1038/tpj.2016.46
Berger, Martin Dave; Stintzing, S; Heinemann, V; Yang, D; Cao, S; Sunakawa, Y; Ning, Y; Matsusaka, S; Okazaki, S; Miyamoto, Y; Suenaga, M; Schirripa, M; Soni, S; Zhang, W; Falcone, A; Loupakis, F; Lenz, H-J (2017). Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Annals of oncology, 28(11), pp. 2780-2785. Oxford University Press 10.1093/annonc/mdx412
